Puma Biotechnology

Nov. 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
Read

Nov. 20, 2021 - Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting
Read

Nov. 19, 2021 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

Nov. 4, 2021 - Puma Biotechnology Reports Third Quarter 2021 Financial Results
Read

Oct. 21, 2021 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

Sept. 21, 2021 - Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
Read

Sept. 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read

Aug. 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results
Read

July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
Read

July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
Read

July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Read

June 4, 2021 - Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Read

June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Read

June 4, 2021 - Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Read

May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
Read

May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results
Read

April 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

Upcoming Events

Nov. 20, 2021 - Society for Neuro-Oncology Annual Meeting
More

Dec. 7-10, 2021 - San Antonio Breast Cancer Symposium
More

Past Events

Oct. 21, 2021 - Puma Biotechnology 3Q-2021 Financial Results Conference Call
More

Sept. 28, 2021 - Cantor Virtual Global Healthcare Conference
More

Sept. 13-15, 2021 - H.C. Wainwright 23rd Annual Global Investment Conference
More

Aug. 5, 2021 - Puma Biotechnology 2Q-2021 Financial Results Conference Call
More

June 4-8, 2021 - ASCO 2021 Annual Meeting
More

May 6, 2021 - Puma Biotechnology 1Q-2021 Financial Results Conference Call
More

Mar. 11, 2021 - Barclays Global Healthcare Conference
More

Mar. 9, 2021 - H.C. Wainwright Global Life Sciences Conference
More

Mar. 2, 2021 - Cowen and Company 41st Annual Health Care Conference
More

Feb. 25, 2021 - Puma Biotechnology 4Q-2020 Financial Results Conference Call
More

Jan. 26-29, 2021 - IASLC 2021 World Conference on Lung Cancers
More

Jan. 21, 2021 - B. Riley Oncology Investor Conference
More

Jan. 15-17, 2021 - ASCO 2021 Gastrointestinal Cancers Symposium
More

Jan. 14, 2021 - 39th Annual J.P. Morgan Healthcare Conference
More

Jan. 11, 2021 - H.C. Wainwright VIRTUAL BioConnect Conference
More

Annual Report Archives

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com

Follow Us:

Nov. 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib) Read

Upcoming Events

Past Events

Nov. 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
Read